Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Twist Bioscience logo — Synthetic DNA for Health & Sustainability

Twist Bioscience

Synthetic DNA for Health & Sustainability

Founded 2013 United States South San Francisco, United States 1309 employees IPO Total: $943.10M Biotechnology, Health Care +1

General Information

Company Name Twist Bioscience
Founded Year 2013
Location United States South San Francisco, United States +6
Employees 1309
Industries Biotechnology, Health Care, Life Sciences
Funding Stage IPO
Social

Get notified when Twist Bioscience moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 07, 2026

Twist Bioscience announced a collaboration with IKP Knowledge Park to co-organize a seminar focused on scaling high-throughput data for biotherapeutic discovery.

Event Participation Sep 01, 2026

Patrick Finn, President and COO of Twist Bioscience, participated as a guest on TD Cowen’s podcast, discussing how AI is reshaping biotechnology and drug discovery.

Award Received Aug 31, 2026

Twist Bioscience is celebrating Emily's recent recognition, highlighted as part of their August achievements.

Feature Release Aug 27, 2026

Twist Bioscience has launched a handy guide to help customers configure Twist Gene Synthesis for their projects, allowing them to match precise requirements quickly.

In The News Aug 19, 2026

Featured on Thenextweb: Anthropic says Claude designed working protein binders, and beat human experts o...

Major Customer Win Aug 17, 2026

Twist Bioscience highlights customer research by showcasing six papers from teams including David R. Liu and Jennifer Doudna, who utilized Twist products.

Get alerts when Twist Bioscience shows new signals

AI Insight

Bounce Watch AI
1 week ago

Twist Bioscience has recently secured significant post-IPO equity funding, including a $250 million round, underscoring strong investor confidence. Concurrently, the company's crucial role in independently validating Anthropic's AI-designed protein binders positions it at the forefront of the rapidly evolving AI drug discovery and synthetic biology fields. This highlights Twist's essential capability in providing high-precision, scalable synthetic DNA and protein services, accelerating groundbreaking research for its biopharma and biotech clientele.

Signal Types
Funding Strategic Alliance Product Validation
Strategic Labels
AI Drug Discovery Enabler Platform Validation Capital Infusion
Next Move: Expansion
·
Impact: 9/10
·
Ideal For: Public Market Investors — Synthetic Biology & AI Biotech

About Twist Bioscience

Twist Bioscience, a leading force in synthetic biology, is based in South San Francisco, California. Founded in 2013, the company's mission—a resonant "Synthetic DNA for Health & Sustainability"—is to empower life science research across diverse fields such as medicine, agriculture, and industrial chemicals.

At its core, Twist Bioscience leverages a proprietary silicon-based manufacturing process to deliver high-precision and high-throughput synthetic DNA. This unparalleled capability allows researchers to drive forward sustainability and health innovations by enhancing the quality and speed of DNA synthesis and sequencing.

The company's value proposition is underscored by a recent $250.00M Post Ipo Equity investment dated 01 August 2026. This capital infusion positions Twist Bioscience robustly in the Biotechnology and Life Sciences sector as it continues to overcome existing efficiency barriers. Without publicly disclosed investors for the latest funding, the company maintains a strategic ambiguity in its investment relations.

Taxonomy: Synthetic Biology, DNA Synthesis, Gene Synthesis, CRISPR, Drug Discovery, Next Gen Sequencing, DNA Data Storage, Variant Libraries, DNA Sequencing, Exome Sequencing, Target Enrichment, Oligonucleotides, Life Sciences, Biopharma Services

Services & Products

Gene Synthesis
Antibody Production and Characterization
Library Preparation Solutions
Variant Library Development
DNA Synthesis on Silicon Platform

Target Customers

Biotechnology Companies Cancer Researchers Pharmaceutical Companies Agricultural Biotechnology Firms Infectious Disease Research Labs Genomic Research Institutions AI Drug Discovery Researchers

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Aug 2026
Post Ipo Equity •••••• 1 •••• •••• 01 May 2026
Post Ipo Equity •••••• - 01 Feb 2022
Post Ipo Equity •••••• - 01 Jan 2020
IPO •••••• - 01 Oct 2018

View All 14 Funding Rounds

Latest News

View All
The US Is Cracking Down on Synthetic DNA — Wired
The US Is Cracking Down on Synthetic DNA
Wired May 06, 2024
OpenAI and Anthropic Sign Letter to Prevent AI-Developed Biological Weapons — Wired
OpenAI and Anthropic Sign Letter to Prevent AI-Developed Biological Weapons
Wired Jun 04, 2026
Anthropic says Claude designed working protein binders, and beat human experts on some — Thenextweb
Anthropic says Claude designed working protein binders, and beat human experts on some
Thenextweb Aug 19, 2026

Twist Bioscience Alternatives & Competitors

View All Alternatives
Twist Bioscience vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care
Compare Twist Bioscience vs Synbio Technologies
Twist Bioscience vs
Molecular Assemblies, Inc.
Molecular Assemblies, Inc. United States

DNA Synthesis Uncompromised

Series B
4 employees
Biotechnology, Health Care
Compare Twist Bioscience vs Molecular Assemblies, Inc.
Twist Bioscience vs
Camena Bioscience
Camena Bioscience United Kingdom

Unlocking access to genes with unparalleled accuracy

Series A
23 employees
Biotechnology, Health Care
Compare Twist Bioscience vs Camena Bioscience
Also compare with: Twist Bioscience vs Evonetix Ltd Evonetix Ltd View all alternatives

FAQ About Twist Bioscience

Synthetic DNA for Health & Sustainability
Twist Bioscience was founded in 2013.
Twist Bioscience is headquartered in South San Francisco, United States.
Twist Bioscience operates in the following industries: Biotechnology, Health Care, Life Sciences.
Twist Bioscience has approximately 1309 employees.
Twist Bioscience has completed 14 funding rounds, raising a total of $943.10M. The latest funding stage is IPO.
Twist Bioscience offers: Gene Synthesis, Antibody Production and Characterization, Library Preparation Solutions, Variant Library Development, DNA Synthesis on Silicon Platform.
Top alternatives and competitors to Twist Bioscience include Synbio Technologies, Molecular Assemblies, Inc., Camena Bioscience, Alta Bioscience Ltd, Integrated DNA Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Twist Bioscience and Synbio Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Twist Bioscience and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy